A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs BI 836880 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 22 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 22 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 02 Feb 2016 New trial record